



**Date:** August 12, 2017

To,  
The Listing Compliance  
**BSE Limited**  
Ground Floor,  
P J Towers Fort,  
Mumbai – 400 001.

Respected Sir/Ma'am,

**Sub: Outcome of Board Meeting held on today i.e. Saturday, August 12, 2017 and submission of Un-Audited Financial Results for the Quarter Ended June 30, 2017.**

**Ref: In the matter of SWORD & SHIELD PHARMA LIMITED  
(Security Id: SWORDNSH Security Code: 531637)**

This is to inform you that the Board of Directors of the Company at its meeting held today (Saturday, August 12, 2017) commenced at 09:00 A.M. (GMT-4) / 06:30 P.M. (IST) and concluded at ~~10:00~~ A.M. (GMT-4) / ~~01:30~~ P.M. (IST) has

1. Approved the Un-Audited Financial Results of the Company along with the Limited Review Report for the Quarter Ended June 30, 2017;
2. Approved the Draft of Directors' Report along with the Annexures of the Company for the Financial Year 2016-2017;
3. Decided to hold the Twenty Second (22<sup>nd</sup>) Annual General Meeting (AGM) of the Company on Saturday, September 30, 2017 at 09:00 A.M. IST at the Registered Office of the Company situated at:

55, World Business House,  
Near Parimal Garden, Ambawadi,  
Ahmedabad – 380 006.

and for the purpose of the Twenty Second (22<sup>nd</sup>) Annual General Meeting the Share Transfer Books of the Company will remain closed from Saturday, September 23, 2017 to Saturday, September 30, 2017 (both the days inclusive).


4. Approved conversion of Partly Paid-up Shares in to Fully Paid-up in respect partly paid-up shares held by Shareholders who have paid the calls for the Partly Paid up Shares.

With reference to point number 4 we would like to inform that the Company had sent Final Call Notices to the Shareholders holding Partly Paid up Shares to pay the

**Registered Office:** 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad – 380 006.

**Website:** [www.swordnshieldpharma.com](http://www.swordnshieldpharma.com) | **Email:** [swordnshield1995@gmail.com](mailto:swordnshield1995@gmail.com)

**Phone:** +91 98250 79759





pending call amount and the Shareholders holding the Partly Paid Up Shares have paid their respective amount on their unpaid shares and now all the Equity Shares of the Company are Fully Paid Up.

The Share Capital of the Company stands as below:

(Amount in INR)

<b>Particulars</b>	<b>After the Call was made</b>	<b>As at March 31, 2017</b>
Authorised Share Capital 6000000 Equity Shares of INR 10/- each	6,00,00,000.00	6,00,00,000.00
Issued Share Capital 5150600 Equity Shares of INR 10/- each	5,15,06,000.00 5150600 Equity Shares of INR 10/- each	5,15,06,000.00 5150600 Equity Shares of INR 10/- each
Subscribed and Paid Up Capital	5,15,06,000.00 (5150600 Equity Shares of INR 10/- each Fully Paid-up)	4,17,32,340.00 (4173234 Equity Shares of INR 10/- each Fully Paid-up)
Subscribed and Partly Paid Up Capital	-	48,86,830.00 (977366 Equity Shares of INR 10/- each on which Rs. 5/- per share is paid-up)
<b>Total</b>	<b>5,15,06,000.00</b>	<b>4,66,19,170.00</b>


The disclosure as required under Para A of Part A of Schedule III of Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements), 2015 read with SEBI Circular Number CIR/CFD/CMD/4/2015 dated September 9, 2015 ("Listing Regulations") is attached as **Annexure – A**.


Kindly take this letter on your record and oblige us.

Thanking You,

Yours Faithfully

For, **SWORD & SHIELD PHARMA LIMITED**

  
**DARSHIL HIRANANDANI**  
**COMPANY SECRETARY AND COMPLIANCE OFFICER**  
**(ACS – 47986)**



**ANNEXURE - A**

**Disclosure in terms of Regulation 30 of the SEBI Listing Regulations, 2015  
read with SEBI Circular Number CIR/CFD/CMD/4/2015  
dated September 9, 2015.**

**1. Forfeiture of shares.**

Not Applicable

**2. Re-issue of forfeited shares or securities, or the issue of shares or securities held in reserve for future issue or the creation in any form or manner of new shares or securities or any other rights, privileges or benefits to subscribe to.**

Not Applicable

**3. Proposal to issue any class of securities.**

Not Applicable

**4. Alterations of capital, including calls**

The Company in its Board Meeting held on Thursday, July 6, 2017 had approved the draft notice to make calls on shareholders in respect of money unpaid on their shares. The Shareholders holding the Partly Paid Up Shares have paid their respective amount of money unpaid on their shares and the Board of Directors, in their Meeting held on August 12, 2017, has approved the conversion of Partly Paid-up shares in to Fully Paid-up.


The Share Capital of the Company now stands as below:

<b>Particulars</b>	<b>After the Call was made</b>	<b>As at March 31, 2017</b>
Authorised Share Capital 6000000 Equity Shares of INR 10/- each	6,00,00,000.00	6,00,00,000.00
Issued Share Capital 5150600 Equity Shares of INR 10/- each	5,15,06,000.00 5150600 Equity Shares of INR 10/- each	5,15,06,000.00 5150600 Equity Shares of INR 10/- each
Subscribed and Paid Up Capital	5,15,06,000.00 (5150600 Equity Shares of INR 10/- each Fully Paid-up)	4,17,32,340.00 (4173234 Equity Shares of INR 10/- each Fully Paid-up)
Subscribed and Partly Paid Up Capital	-	48,86,830.00 (977366 Equity Shares of INR 10/- each on which Rs. 5/- per share is paid-up)
<b>Total</b>	<b>5,15,06,000.00</b>	<b>4,66,19,170.00</b>

**Registered Office:** 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad - 380 006

**Website:** www.swordnshieldpharma.com | **Email:** swordnshield1995@gmail.com

**Phone:** 91 98250 79759






**5. Change in the terms regarding redemption / cancellation / retirement in whole or in part of any securities issued by the listed entity:**

Not Applicable

For, **SWORD & SHIELD PHARMA LIMITED**

*Darshan*  
**DARSHIL HIRANANDANI**

**COMPANY SECRETARY AND COMPLIANCE OFFICER  
(ACS - 47986)**





**B. K. PATEL & CO**  
Chartered Accountants

301, 'SAMRUDDHI', Opp. Old High Court, Navjivan P.O., AHMEDABAD - 380 014. Gujarat.  
PHONES : 079 - 2754 4927, 2754 1151  
Email : [bkpatelandco@gmail.com](mailto:bkpatelandco@gmail.com)

**Limited Review Report**


To,  
The Board of Directors,  
**Sword & Shield Pharma Limited.**  
Ahmedabad

We have reviewed the accompanying statement of Un-Audited Financial Results (the statements) together with the relevant notes thereon of **Sword & Shield Pharma Limited**, Ahmedabad for the quarter ended on **June 30, 2017** prepared by the Company in pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a review report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by independent auditor of entity' issued by The Institute of Chartered Accountants of India which requires that we plan and perform the review to obtain moderate assurance as to whether the financial information's are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is subsequently less in scope than an audit conducted in accordance with standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified during the course an Audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with Indian accounting standards as specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, or that it contains any material misstatement.

For, B. K. PATEL & CO  
Chartered Accountants  
Firm Regn No. 112647W




12-8-2017  
Ahmedabad

  
K. D. Patel  
Partner  
Membership No. 39919


**SWORD AND SHIELD PHARMA LIMITED**  
**CIN: L24231GJ1995PLC024809**  
**Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi,**  
**Ahmedabad – 380 006**  
**Website: www.swordnshieldpharma.com**  
**Contact: +91 98250 79759**

**Un-Audited Financial Results for the Quarter Ended June 30, 2017**

Particulars		Amount in INR	
		Quarter Ended	
		3 Months Ended	3 Months Ended
		30-Jun-17	30-Jun-16
		Un-Audited	Un-Audited
<b>PART I</b>			
<b>1</b>	<b>INCOME</b>		
	Revenue from Operations	237662.00	144619.00
	Other Income	0.00	0.00
	<b>Total Income</b>	<b>237662.00</b>	<b>144619.00</b>
<b>2</b>	<b>EXPENSES</b>		
(a)	Cost of Material Consumed	0.00	0.00
(b)	Purchase of Stock-In-Trade	0.00	0.00
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	0.00	0.00
(d)	Employee Benefit Expense	103275.00	133745.00
(e)	Finance Cost	0.00	0.00
(f)	Depreciation, Depletion and Amortisation Expense	0.00	0.00
(g)	Other Expense	726908.00	328326.00
	<b>Total Other Expenses</b>	<b>726908.00</b>	<b>328326.00</b>
	<b>Total Expenses</b>	<b>830183.00</b>	<b>462071.00</b>
<b>3</b>	<b>Total Profit before Exceptional Items and Tax</b>	<b>-592521.00</b>	<b>-317452.00</b>
<b>4</b>	Exceptional Items	0.00	0.00
<b>5</b>	<b>Total Profit before Tax</b>	<b>-592521.00</b>	<b>-317452.00</b>
<b>6</b>	Tax Expense		
<b>7</b>	Current Tax	0.00	16475.00
<b>8</b>	Deferred Tax	0.00	0.00
<b>9</b>	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>16475.00</b>
<b>10</b>	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>	<b>-592521.00</b>	<b>-333927.00</b>
<b>12</b>	Profit / (Loss) from discontinued operations before tax	0.00	0.00
<b>13</b>	Tax Expenses of discontinued operations	0.00	0.00
<b>14</b>	<b>Net Profit / (Loss) from discontinued operations after tax</b>	<b>0.00</b>	<b>0.00</b>
<b>15</b>	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00
<b>16</b>	<b>Total Profit / (Loss) for the period</b>	<b>-592521.00</b>	<b>-333927.00</b>
<b>17</b>	Other Comprehensive Income net of Taxes	0.00	0.00
<b>18</b>	<b>Total Comprehensive Income for the Period</b>	<b>-592521.00</b>	<b>-333927.00</b>
<b>19</b>	<b>Total profit or loss attributable to</b>		
	Profit or loss, attributable to owners of parents	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00
<b>20</b>	<b>Total comprehensive income for the period attributable to</b>	<b>0.00</b>	<b>0.00</b>
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00
<b>21</b>	<b>Details of Equity Share Capital</b>		
	Paid-Up Equity Share Capital	46619170.00	46619170.00
	Face Value of Equity Share Capital	10.00	10.00
<b>22</b>	<b>Details of Debt Securities</b>		
	Paid-Up Debt Capital	0.00	0.00
	Face Value of Debt Securities	0.00	0.00
<b>23</b>	Reserves Excluding Revaluation Reserves	-47987118.55	-4533995.60



*[Handwritten Signature]*



24	Debenture Redemption Reserve	0.00	0.00
25	<b>Earnings Per Share</b>		
(i)	<b>Earnings Per Share for continuing operations</b>		
	Basic Earnings / (Loss) per share from continuing operations	-0.115	-0.065
	Diluted Earnings / (Loss) per share from continuing operations	-0.115	-0.065
(ii)	<b>Earnings Per Share for discontinued operations</b>		
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00
(iii)	<b>Earnings per Equity Share</b>		
	Basic Earnings / (Loss) per share from continuing and discontinued operations	-0.115	-0.065
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	-0.115	-0.065
26	Debt Equity Ratio	-1.47	1.24
27	Debt Service Coverage Ratio	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00

The Company adopted Indian Accounting Standards (IndAS) from April 1, 2017 as per road map released by Ministry of Corporate Affairs (MCA). Reconciliation of Net Profit after tax as previously reported under Indian GAAP and IndAS for the quarter ended June 30, 2016 is as follows:

Description	30-Jun-16
	Unaudited
Net Profit as per Previous Indian GAAP	-333927.00
Net Profit as per IndAS	-333927.00

#### NOTES

- The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 12, 2017.
- The Limited Review of the results has been completed by the Statutory Auditors of the Company.
- As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
- The financial results for the quarter ended 30 June 2016 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
- Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
- Results are available at Company's website [www.swordnshieldpharma.com](http://www.swordnshieldpharma.com) and also at [www.bseindia.com](http://www.bseindia.com).

For, SWORD & SHIELD PHARMA LIMITED

PRAVINBHAI PATEL

Place	Pennyslavania	MANAGING DIRECTOR
Date	12-Aug-17	DIN: 01877446

